Key result
Long-term systemic administration of thymosin beta 4 significantly reduced mean infarct volume by 43% compared to vehicle in a rat model of permanent myocardial ischemia.
Why the study?
Does systemic administration of thymosin beta 4 reduce infarct size and improve hemodynamic performance in rat models of ischemic myocardial injury?
Population
Male Sprague-Dawley rats subjected to permanent left anterior descending coronary artery occlusion or…
Comparison
Thymosin beta 4 5.37 mg/kg intra-peritoneally… vs Vehicle 5 mL/kg IP. Sham-operated animals were…
Design
Preclinical
Follow-up
28 days and 23.5 hours
Authors
Loading...
Does not support clinical use; leaves open translation of thymosin beta 4 to human myocardial infarction therapy.
Does systemic administration of thymosin beta 4 reduce infarct size and improve hemodynamic performance in rat models of ischemic myocardial injury?
Effect estimate: 43% reduction
Absolute Event Rate: 5.2% vs 9.1%
p-value: p=<0.01
Systemic administration of thymosin beta 4 reduces infarct size and preserves hemodynamic function in rat models of myocardial infarction, suggesting potential as a cardioprotective therapy.
Bao et al. (2013) studied Ischemic myocardial injury (n=70). Thymosin beta 4 vs. Vehicle (sterile water) was evaluated on Infarct volume at 28 days (43% reduction, p=<0.01). Long-term systemic administration of thymosin beta 4 significantly reduced mean infarct volume by 43% compared to vehicle in a rat model of permanent myocardial ischemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: